Fundraising Fox
Artelo Biosciences
NASDAQ: ARTLSolana Beach, US · Nevada corporation
Find your way into Artelo Biosciences
Sign up to see every warm intro you have to Artelo Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Artelo Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Artelo Biosciences develops therapeutic treatments by modifying lipid signaling pathways to treat cancer and other serious conditions at the clinical stage.
Founders & leadership
GD
Gregory D. GorgasPresident & CEOGregory D. Gorgas holds an MBA from University of Phoenix and a BA in Economics from California State University, Northridge. He has worked in pharmaceutical and biotech commercialization roles spanning three decades, including positions at Upjohn, Chiron, and IDEC (where he led sales for Rituxan's launch), prior to co-founding Theragence and serving as Senior Vice President of Commercial at Mast Therapeutics before becoming President and CEO of Artelo Biosciences in 2017.
PO
Peter O'BrienSenior Vice President Europe / Nasdaq2017–2021Co-founder of Ventry Technologies, an energy efficiency company; previously worked on HVO fuel deployment in Ireland and energy infrastructure projects across Europe, the Middle East, and Africa.
Board
CM
Connie MatsuiBoard director
SK
Steven KellyBoard director
DB
GR
Gregory R. ReyesBoard director
TA
Tamara A. FavoritoBoard director
RM
R. Martin EmanueleBoard director
Reported raises · per SEC filings
Form D private placements$33.4M disclosed across 14 of 15 rounds · 2017–2026
▶$11MraisedApr 2026 · 2 investors · BiotechnologyRule 506(b)
▶$11MraisedApr 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- R. Martin EmanueleDirector
- Connie MatsuiDirector
- Mark SpringExecutive Officer
- Gregory R. ReyesDirector
- Tamara A. FavoritoDirector
- Steven KellyDirector
- Gregory D. GorgasExecutive Officer, Director
- Offering amount
- $11M
- Amount sold
- $11M
- Sales commissions
- $880K
- Proceeds to insiders
- $575.5K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Mar 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$113KraisedMar 2026 · 1 investors · BiotechnologyRule 506(b)
▶$113KraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- Mark SpringExecutive Officer
- Connie MatsuiDirector
- Gregory R. ReyesDirector
- Tamara A. FavoritoDirector
- R. Martin EmanueleDirector
- Steven KellyDirector
- Gregory D. GorgasExecutive Officer, Director
- Offering amount
- $113K
- Amount sold
- $113K
- First sale
- Mar 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$237.3KraisedMar 2026 · 1 investors · BiotechnologyRule 506(b)
▶$237.3KraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- Connie MatsuiDirector
- Tamara A. FavoritoDirector
- Gregory R. ReyesDirector
- Steven KellyDirector
- Mark SpringExecutive Officer, Director
- R. Martin EmanueleDirector
- Gregory D. GorgasExecutive Officer, Director
- Offering amount
- $237.3K
- Amount sold
- $237.3K
- First sale
- Mar 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$315KraisedMar 2026 · 1 investors · BiotechnologyRule 506(b)
▶$315KraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory D. GorgasExecutive Officer, Director
- Douglas BlayneyDirector
- Gregory R. ReyesDirector
- R. Martin EmanueleDirector
- Mark SpringExecutive Officer
- Steven KellyDirector
- Connie MatsuiDirector
- Tamara A. FavoritoDirector
- Offering amount
- $315K
- Amount sold
- $315K
- First sale
- Mar 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$500KraisedFeb 2026 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedFeb 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- Tamara A. FavoritoDirector
- Gregory D. GorgasExecutive Officer, Director
- R. Martin EmanueleDirector
- Mark SpringExecutive Officer
- Connie MatsuiDirector
- Gregory R. ReyesDirector
- Steven KellyDirector
- Offering amount
- $50.5M
- Amount sold
- $500K
- First sale
- Jan 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.7MraisedNov 2025 · 14 investors · BiotechnologyRule 506(b)
▶$3.7MraisedNov 2025 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- Mark SpringExecutive Officer
- Gregory R. ReyesDirector
- Gregory D. GorgasExecutive Officer, Director
- R. Martin EmanueleDirector
- Connie MatsuiDirector
- Steven KellyDirector
- Tamara A. FavoritoDirector
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- First sale
- Oct 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$9.5MraisedAug 2025 · 18 investors · BiotechnologyRule 506(b)
▶$9.5MraisedAug 2025 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory R. ReyesDirector
- Connie MatsuiDirector
- Gregory D. GorgasExecutive Officer, Director
- Steven KellyDirector
- Tamara A. FavoritoDirector
- R. Martin EmanueleDirector
- Douglas BlayneyDirector
- Offering amount
- $9.5M
- Amount sold
- $9.5M
- First sale
- Aug 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.4MraisedJul 2025 · 8 investors · BiotechnologyRule 506(b)
▶$1.4MraisedJul 2025 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Connie MatsuiDirector
- Steven KellyDirector
- Douglas BlayneyDirector
- Gregory R. ReyesDirector
- Tamara A. FavoritoDirector
- R. Martin EmanueleDirector
- Gregory D. GorgasExecutive Officer, Director
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- First sale
- Jun 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$10.3Mvaluation at IPOOct 2020 · $0.75/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 7
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
PerplexityAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Companies working in the same space as Artelo Biosciences.
In the news
Frequently asked questions
- What does Artelo Biosciences do?
- Artelo Biosciences develops therapeutic treatments by modifying lipid signaling pathways to treat cancer and other serious conditions at the clinical stage.
- How much funding has Artelo Biosciences raised?
- Artelo Biosciences has disclosed $33.4M raised across 14 of its 15 known rounds.
- Where is Artelo Biosciences headquartered?
- Artelo Biosciences is headquartered in Solana Beach, US.